Abelacimab
Abelacimab has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Feb 4, 2026: “Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial”.
1 paper studies it1 findingUpdated
See all 1 papers on abelacimab
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country; 4 trials, none about aging.
“Both abelacimab doses were associated with significantly less major or CRNM bleeding compared with rivaroxaban in those 75 years or older (hazard ratio [HR], 0.32; 95% CI, 0.17-0.60”
- 1 lab in 1 country
- 4 trials, none about aging
- 1 of 1 finding with company ties
- 4 of 4 trials sponsored by its developers
- Human trial1
Studies in people
1 study gave abelacimab to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Lowers the risk of bleedingHR, 0.32; 95% CI, 0.17-0.60 | Randomized trialmonthly | 1,287 peopleBoth≥75 yearsMidlife adults; Older adults; The oldest old; atrial fibrillation | JAMA cardiology, Feb 4, 2026 |
What is abelacimab linked with?
1Studies link abelacimab with bleeding.
Bleeding
downin humans1HR 0.32
1 study
Bleeding
downin humans1HR 0.32
Abelacimab lowers the risk of bleeding in humans (atrial fibrillation) (HR, 0.32; 95% CI, 0.17-0.60).
“Both abelacimab doses were associated with significantly less major or CRNM bleeding compared with rivaroxaban in those 75 years or older (hazard ratio [HR], 0.32; 95% CI, 0.17-0.60”
Human trialatrial fibrillation90 mg monthly
JAMA cardiology
Who is developing abelacimab?
2 companies: Novartis Pharmaceuticals and Anthos Therapeutics.
Trial sponsors
Company3 trialsPhase 34,937 people
Novartis Pharmaceuticals Corporation
Company1 trialPhase 32,500 people